Company / Net Income
Bristol Myers Squibb Net Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
$7.1B
FY2025
5-year range
-$9.0B / $7.1B
FY2021-FY2025
Trend
+178.8%
vs FY2024
Sector context
#8 of 216
Health Care
What the data says
Among 216 Health Care companies, Bristol Myers Squibb is in the top 4% for net income. Net Income has fluctuated over the past 10 years, ranging from -$9.0B in FY2022 to $7.1B in FY2025.
Based on SEC 10-K filings.
$7.1B in FY2025. Top quartile in the Health Care sector.
Remained stable around $7.1B over the past 2 years.
Health Care sector context is included.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 4% in Health CareTop 4% of 216This company $7.1B Sector average $454.3M
▼
+1452.7% above sector average
Key checks
Key Insights
- In FY2025, net income increased 178.8% year-over-year.
- Ranks #8 out of 216 companies in the Health Care sector.
- Lowest net income in the period was in FY2022.
Company context
Key Data Points
- High Piotroski F-Score: 8/9 (strong financial health signals)
- Altman Z-Score 0.85 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
- Strong return on equity: 32.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $7.1B | +178.8% |
| FY2024 | -$8.9B | -227.9% |
| FY2023 | $7.0B | +177.6% |
| FY2022 | -$9.0B | -362.1% |
| FY2021 | $3.4B | +138.1% |
| FY2020 | -$9.0B | -995.2% |
| FY2019 | $1.0B | -77.4% |
| FY2018 | $4.5B | +342.6% |
| FY2017 | $1.0B | -49.8% |
| FY2016 | $2.0B | -21.8% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026